Fig. 4: gCTRP9 promotes NLRP3 degradation in a lysosome-dependent manner.
From: CTRP9 as a myokine mitigates sarcopenia via the LAMP-2A/NLRP3 pathway
A Western blot analysis of NLRP3, Fbxo32, IL-18, IL-1β and Caspase-1 p20 protein expression in the siNC and siCTRP9 groups of C2C12 myotubes; GAPDH serves as the loading control (n = 3). B qPCR analysis of mRNA levels of NLRP3 and IL-1β in the siNC and siCTRP9 groups of C2C12 myotubes. (n = 3). C ELISA quantification of secreted IL-1β levels in the siNC and siCTRP9 groups of C2C12 myotubes. (n = 3). D qPCR analysis of NLRP3 mRNA levels in C2C12 myotubes treated with PBS or gCTRP9 (n = 3). E Western blot analysis of NLRP3 protein expression in C2C12 cells treated with cycloheximide (CHX) in the presence or absence of gCTRP9; GAPDH serves as the loading control (n = 3). F Western blot analysis of NLRP3 protein expression in C2C12 cells pre-treated with LPS and gCTRP9, followed by the indicated inhibitors: MG132 (proteasome inhibitor), chloroquine (CQ, lysosomal inhibitor), and 3-methyladenine (3-MA, autophagy inhibitor); GAPDH serves as the loading control (n = 3). Data are presented as mean ± SEM.
